5xcu: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptide== | ==Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptide== | ||
<StructureSection load='5xcu' size='340' side='right' caption='[[5xcu]], [[Resolution|resolution]] 2.45Å' scene=''> | <StructureSection load='5xcu' size='340' side='right'caption='[[5xcu]], [[Resolution|resolution]] 2.45Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5xcu]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5XCU OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[5xcu]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5XCU OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5XCU FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5xcs|5xcs]], [[5xcv|5xcv]], [[5xcq|5xcq]], [[5xcx|5xcx]], [[5xct|5xct]], [[5xcr|5xcr]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5xcs|5xcs]], [[5xcv|5xcv]], [[5xcq|5xcq]], [[5xcx|5xcx]], [[5xct|5xct]], [[5xcr|5xcr]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5xcu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5xcu OCA], [http://pdbe.org/5xcu PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5xcu RCSB], [http://www.ebi.ac.uk/pdbsum/5xcu PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5xcu ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 21: | Line 21: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Arimori, T]] | [[Category: Arimori, T]] | ||
[[Category: Takagi, J]] | [[Category: Takagi, J]] | ||
Revision as of 09:46, 14 October 2020
Crystal structure of 12CA5 Fv-clasp fragment with its antigen peptideCrystal structure of 12CA5 Fv-clasp fragment with its antigen peptide
Structural highlights
Publication Abstract from PubMedAntibody fragments are frequently used as a "crystallization chaperone" to aid structural analysis of complex macromolecules that are otherwise crystallization resistant, but conventional fragment formats have not been designed for this particular application. By fusing an anti-parallel coiled-coil structure derived from the SARAH domain of human Mst1 kinase to the variable region of an antibody, we succeeded in creating a novel chimeric antibody fragment of approximately 37 kDa, termed "Fv-clasp," which exhibits excellent crystallization compatibility while maintaining the binding ability of the original IgG molecule. The "clasp" and the engineered disulfide bond at the bottom of the Fv suppressed the internal mobility of the fragment and shielded hydrophobic residues, likely contributing to the high heat stability and the crystallizability of the Fv-clasp. Finally, Fv-clasp antibodies showed superior "chaperoning" activity over conventional Fab fragments, and facilitated the structure determination of an ectodomain fragment of integrin alpha6beta1. Fv-clasp: An Artificially Designed Small Antibody Fragment with Improved Production Compatibility, Stability, and Crystallizability.,Arimori T, Kitago Y, Umitsu M, Fujii Y, Asaki R, Tamura-Kawakami K, Takagi J Structure. 2017 Sep 6. pii: S0969-2126(17)30264-2. doi:, 10.1016/j.str.2017.08.011. PMID:28919443[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||